Dafinace 5mg

Haloperidol 5mg

Dosing & Uses
Adult

Dosage Forms & Strengths

tablet

  • 0.5 mg
  • 1 mg
  • 2 mg
  • 5 mg
  • 10 mg
  • 20 mg

oral concentrate

  • 2 mg/mL

injectable solution, lactate

  • 5 mg/mL

injectable solution, decanoate

  • 50 mg/mL
  • 100 mg/mL

Schizophrenia, Psychosis

PO

  • Moderate disease, 0.5-2 mg q8-12hr initially
  • Severe disease, 3-5 mg q8-12hr initially; not to exceed 30 mg/day

IM lactate (prompt-acting)

  • 2-5 mg q4-8hr PRN; may require q1hr in acute agitation; not to exceed 20 mg/day

IM decanoate (depot)

  • Initial: IM dose 10-20 times daily PO dose administered monthly; not to exceed 100 mg; if conversion requires initial dose >100 mg, administer in 2 injections (eg, 100 mg initially, then remainder in 3-7 days)
  • Maintenance: Monthly dose 10-15 times daily PO dose 

IV (Off-label)

  • May be needed for ICU delirium; use only haloperidol lactate for IV administration; do not use haloperidol decanoate
  • 2-10 mg initially, depending on degree of agitation; if response inadequate, may repeat bolus q15-30min, sequentially doubling initial bolus dose; when calm achieved, administer 25% of last bolus dose q6hr; taper dose after patient is controlled  
  • Monitor ECG and QT interval (QT prolongation may occur with cumulative doses ≥35 mg; torsades de pointes reported with single doses ≥20 mg)

Tourette Disorder

0.5-2 mg PO q8-12hr initially; if severe symptoms necessitate increased dosage, titrate upward to 3-5 mg PO q8-12hr; if patient remains inadequately controlled, daily doses up to 100 mg have been used (safety not determined) 

Pediatric

Dosage Forms & Strengths

tablet

  • 0.5 mg
  • 1 mg
  • 2 mg
  • 5 mg
  • 10 mg
  • 20 mg

oral concentrate

  • 2 mg/mL

injectable solution, lactate

  • 5 mg/mL

injectable solution, decanoate

  • 50 mg/mL
  • 100 mg/mL

Schizophrenia, Psychosis/Sedation

<3 years: Safety and efficacy not established

3-12 years (15-40 kg): 0.25-0.5 mg/day PO divided q8-12hr initially; may be increased by 0.5 mg/day every 5-7 days PRN; maintenance: 0.05-0.15 mg/kg/day PO divided q8-12hr   

6-12 years: Lactate (prompt-acting): 1-3 mg IM q4-8hr PRN; not to exceed 0.15 mg/kg/day 

>12 years: Moderate disease, 0.5-2 mg PO q8-12hr initially; severe disease, 3-5 mg PO q8-12hr; not to exceed 30 mg/day 

Tourette Disorder

<3 years: Safety and efficacy not established

3-12 years: 0.5 mg/day PO initially; dose increased by 0.5 mg every 5-7 days until therapeutic effect achieved, then reduced to lowest effective maintenance level of 0.05-0.075 mg/kg/day PO divided q8-12hr 

>12 years: 0.5-2 mg PO q8-12hr initially; if severe symptoms necessitate increased dosage, titrate upward to 3-5 mg PO q8-12hr; if patient remains inadequately controlled, daily doses up to 100 mg have been used (safety not determined)

Behavioral Disorders

<3 years: Safety and efficacy not established

3-12 years: 0.5 mg/day PO initially; dose increased PRN by 0.5 mg every 5-7 days until therapeutic effect achieved, then reduced to lowest effective maintenance level of 0.05-0.075 mg/kg/day PO divided q8-12hr  

Acute Agitation

<12 years: Safety and efficacy not established

>12 years: 0.5-3 mg PO, repeated in 1 hour PRN; alternatively, 2-5 mg IM, repeated in 1 hr PRN

Geriatric

Schizophrenia, Psychosis

PO: Lower initial doses and more gradual adjustments recommended; 0.25-0.5 mg PO q8-12hr initially

IM lactate (prompt-acting): Lower adult doses and longer dosing intervals recommended compared with typical adult doses

IM decanoate (depot): Lower initial doses and more gradual adjustments recommended; monthly dose 10-15 times daily PO dose

IV (off-label): 0.25-0.5 mg IV q4hr; use only lactate (not decanoate) for IV administration; monitor with ECG for prolonged QT interval

Not approved for dementia-related psychosis, because of increased risk of cardiovascular or infectious related deaths (see Black Box Warnings)

Tourette Disorder

Lower initial doses and more gradual adjustments recommended; 0.25-0.5 mg PO q8-12hr initially

Dosing Considerations

Elderly at higher risk for tardive dyskinesia associated with higher-potency antipsychotic agents such as haloperidol because of higher ratios of dopaminergic blockage to adrenergic/anticholinergic blockade

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Dafinace 5mg only for the indication prescribed.